Skip to content

Savara SVRA Investing Cash Flow

Investing Cash Flow at other companies

XER
Xeris Biopharma Holdings, Inc.XERS
-$325K-2,400%
Innoviva, Inc. logo
Innoviva, Inc.INVA
$37.01M+207%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$52.59M+71.7%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
-$11.32M+42.9%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
-$15.08M
TRV
Trevi Therapeutics, Inc.TRVI
$16.97M+270%

Other financials

Income statement

See full
Revenue-
Operating income-$39.0M-37.1%
Net income-$37.3M-40.0%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$38.8M+98.4%
Total debt$30.1M+1.8%
Total equity$176.0M+19.1%
Total assets$221.6M+17.1%

Cash flow

See full
Operating cash flow-$33.0M-21.5%
CapEx$54.0K+1,700%
Free cash flow-$33.1M-21.7%

Valuation

See full
Market cap$1.19B+134%
Enterprise value$1.19B+127%
P/S4,648.7×

Profitability

See full
Operating margin-19,183.3%
Net margin-19,305.1%
FCF margin-15,518.7%

Returns & leverage

See full
Return on equity-80%+4.7pp
Debt / equity0.2×0.0×
Current ratio13.5×-1.4×

Where this comes from

Reported directly by Savara in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Savara’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Savara's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Savara's investing cash flow?
Savara (SVRA) reported investing cash flow of $38.78M in Q1 2026.
How has Savara's investing cash flow changed year-over-year?
Savara's investing cash flow increased by 32.2% year-over-year, from $29.33M to $38.78M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.